RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Canaccord ups Price Target to $7I believe that too Scarle --that we've done at least as good a job as any analyst out there if not better lately. Then again, the bar isn't too high in my opinion! We've had a few things right and some wrong on this board. I would say Abrahams was one of the few that got Trogarzo right though. But I believe it was JFM or maybe Qwerty that often cautioned about the slow ramp due to delivery method and new type of HIV drug. So a few on this board were in the right direction. I wasn't one - I believed those large market numbers (which may still be sort of correct, but isn't really the addressable market), but didn't realize doctors view that it's purely a scavenger last attempt drug until THTX convinces them otherwise.
But I think we understood the NASH data hints and research much better than the analysts except for Doug Loe who was on it very early. I think we are also quite a bit ahead in understanding the opportunity of the SORT1+ platform, the risks, and what to look for. Some of the analyst likely know it, but they aren't at all forward-looking enough to do a deep dive in to what the data has shown so far, comparing it to others in the industry like we have, and what it could amount to (like we also have) as a first-in-class PDC in all those cancers.
I think we understood the need for a global pharma exec in there too for this next phase of corporate development (as did the Board), and lately the need for more global financial experience on the Board. Hopefully they'll see that too.
So, yes, we've understood some things quite well with the help of many experienced people on this board. But we've also been blind at times to other facets of the businness and that's what hurt us over the last 24 months. I'd also say we understood the shrinking audience for the stock and the implications there quite well --mostly because we felt it in our pockets. I'd also like to think from Leah's conversation with Scarlet that they finally get it too and it is now part of their overall business strategy.
Despite that, I'd still like to see a few credible global healthcare firms do research on this simply so that the audience can be built back up as we get the hard data in humans from all these trials. As we've seen, sometimes even good developments don't get fully reflected in the price and given how we've all suffered a huge opportunity cost in THTX versus so many other ideas out there, I don't know about you all, but I want to see future developments get more than factored in and for us to be in that upper tier of valuations for growing biotechs with exciting portfolio of opportunities. We deserve it if the data comes in positively. That will be the driver, but it's also nice to build the audience to be there for it on that day it comes in!